Venetoclax is an option in B‐cell prolymphocytic leukaemia following progression on B‐cell receptor pathway inhibitors

Nikila Patil; Richard G. Went

doi:10.1111/bjh.15912

Venetoclax is an option in B‐cell prolymphocytic leukaemia following progression on B‐cell receptor pathway inhibitors

British Journal of Haematology ◽

10.1111/bjh.15912 ◽

2019 ◽

Vol 186 (4) ◽

Cited By ~ 2

Author(s):

Nikila Patil ◽

Richard G. Went

Keyword(s):

B Cell ◽

Cell Receptor ◽

B Cell Receptor ◽

Prolymphocytic Leukaemia

Download Full-text

Role of the proto-oncogene product Cbl in B cell receptor signalling

Immunology Letters ◽

10.1016/s0165-2478(97)86852-6 ◽

1997 ◽

Vol 56 (1-3) ◽

pp. 4

Author(s):

L Smit

Keyword(s):

B Cell ◽

Cell Receptor ◽

B Cell Receptor ◽

Receptor Signalling

Download Full-text

CD5 and other superantigens as 'ticklers' of the B-cell receptor

Immunology Today ◽

10.1016/s0167-5699(97)01215-2 ◽

1998 ◽

Vol 19 (3) ◽

pp. 106-108 ◽

Cited By ~ 13

Author(s):

R Pospisil

Keyword(s):

B Cell ◽

Cell Receptor ◽

B Cell Receptor

Download Full-text

Review for "B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma"

10.1002/hon.2816/v1/review1 ◽

2020 ◽

Author(s):

Caroline Besson

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Eradication Therapy ◽

B Cell Lymphoma ◽

Cell Receptor ◽

B Cell Receptor ◽

Large B Cell Lymphoma ◽

B Cell Receptor Signaling ◽

Cell Receptor Signaling ◽

Large B Cell

Download Full-text

B cell receptor editing in tolerance and autoimmunity

Frontiers in Bioscience ◽

10.2741/2217 ◽

2007 ◽

Vol 12 (1) ◽

pp. 2136 ◽

Cited By ~ 3

Author(s):

Hilla Azulay-Debby

Keyword(s):

B Cell ◽

Cell Receptor ◽

B Cell Receptor ◽

Receptor Editing

Download Full-text

Faculty Opinions recommendation of Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1007572.115357 ◽

2002 ◽

Author(s):

Vincent Ling

Keyword(s):

B Cells ◽

B Cell ◽

Constitutive Expression ◽

Cell Receptor ◽

B Cell Receptor ◽

Interleukin 4 ◽

Inducible Costimulator ◽

Interleukin 4 Receptor

Download Full-text

Faculty Opinions recommendation of Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1029979.351430 ◽

2005 ◽

Author(s):

Marcus Clark

Keyword(s):

B Cell ◽

Cell Receptor ◽

B Cell Receptor ◽

Receptor Signaling ◽

B Cell Receptor Signaling ◽

Deficient Mice ◽

Cell Receptor Signaling

Download Full-text

Faculty Opinions recommendation of CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1098757.555275 ◽

2008 ◽

Author(s):

E Charles Snow

Keyword(s):

B Cell ◽

Cell Activation ◽

Cell Receptor ◽

B Cell Receptor ◽

B Cell Activation ◽

Membrane Bound

Download Full-text

Faculty Opinions recommendation of The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1115714.572291 ◽

2008 ◽

Author(s):

George Yap

Keyword(s):

B Cell ◽

Subcellular Location ◽

Cell Receptor ◽

B Cell Receptor ◽

Toll Like Receptor

Download Full-text

Faculty Opinions recommendation of The membrane skeleton controls diffusion dynamics and signaling through the B cell receptor.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.2270956.1891054 ◽

2010 ◽

Author(s):

Robert Carter

Keyword(s):

B Cell ◽

Cell Receptor ◽

Membrane Skeleton ◽

B Cell Receptor ◽

Diffusion Dynamics

Download Full-text

Faculty Opinions recommendation of Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718490094.793497269 ◽

2014 ◽

Author(s):

Stephan Stilgenbauer

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Cell Receptor ◽

Anticancer Therapy ◽

B Cell Receptor ◽

B Cell Malignancies ◽

B Cell Receptor Signaling ◽

Cell Receptor Signaling

Download Full-text